Working... Menu
Trial record 16 of 54 for:    Inclusion Body Myositis

Study of Pioglitazone in Sporadic Inclusion Body Myositis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03440034
Recruitment Status : Recruiting
First Posted : February 20, 2018
Last Update Posted : May 29, 2019
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).

Condition or disease Intervention/treatment Phase
Myositis Inclusion Body Myositis Muscular Diseases Musculoskeletal Disease Neuromuscular Diseases Nervous System Diseases Drug: Pioglitazone Phase 1

Detailed Description:
This is a 52-week, Phase 1, open-label, single center, proof of concept study of FDA-approved pioglitazone in adult patients with sporadic inclusion body myositis (sIBM). The trial consists of a 4-week screening period;16-week "lead-in" period during which all subjects are observed off-treatment. At Week 16, all subjects will be started on pioglitazone at a dose of 30 mg daily. The dose will be uptitrated to a goal dose of 45 mg daily after 2 weeks; 32-week treatment period with all subjects on 45 mg daily dose of pioglitazone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, non-randomized trial in 15 patients with sIBM
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis
Actual Study Start Date : May 22, 2018
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : December 31, 2020

Arm Intervention/treatment
Experimental: Pioglitazone
All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
Drug: Pioglitazone
Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
Other Name: Actos

Primary Outcome Measures :
  1. Change from baseline in Peroxisome proliferator-activated receptor gamma coactivator 1-alpha target gene expression [ Time Frame: 4 weeks, 16 weeks, 32 weeks after baseline ]
    Effect of 45 milligram pioglitazone dose on the expression of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha target genes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 50 years
  • Diagnosis of sporadic inclusion body myositis (sIBM) based on the sIBM Diagnostic Criteria established by the 2010 European Neuromuscular Center.
  • Must be able to ambulate at least 20 feet, with or without the use of an assistive device. Patients may not use another person, wall, or furniture for support.
  • Must be able to rise from a chair without support from another person or device.
  • Premenopausal women must have a negative serum pregnancy test prior to dosing with study medication.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.

Exclusion Criteria:

  • A history of diabetes mellitus, or prior or concurrent treatment with any diabetes therapy
  • Use of chronic immunosuppressive therapy including corticosteroids or intravenous immune globulin (IVIG) within the past 6 months.
  • Use of Vitamin E supplements within the past 3 months
  • Creatine kinase (CK) > 15x the upper limit of normal
  • Any condition other than sIBM that causes significant muscle pain, muscle weakness, muscle atrophy, or joint pain. This includes but is not limited to such neurologic and neuromuscular diseases as polymyositis or dermatomyositis, myasthenia gravis, amyotrophic lateral sclerosis, stroke, multiple sclerosis, epilepsy, muscular dystrophy, fibromyalgia, rheumatoid arthritis, spinal cord injury or degenerative disease of the spine. Osteoarthritis is not exclusionary unless it limits the patient's ability to comply with study tasks. Patients with a history of a hip or vertebral fracture within the past year or surgical hip or knee replacement within the past six months will be excluded.
  • Patients receiving any medications or substances that are inhibitors or inducers of CYP2C8 are ineligible. These medications include but are not limited to Gemfibrozil, Rifampin, and warfarin.
  • Pregnant women
  • History of cancer less than five years prior, other than local basal or squamous cell cancer.
  • Patient has any medical condition or laboratory finding during screening, which, in the investigator's opinion may interfere with participation, confound the results, or pose any additional risk to the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03440034

Layout table for location contacts
Contact: Brittany Adler, MD 410-550-6962
Contact: Jemima Albayda, MD 410-550-6962

Layout table for location information
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21224
Contact: Brittany Adler, MD    410-550-6962   
Contact: Jemima Albayda, MD    410-550-6962   
Sponsors and Collaborators
Johns Hopkins University
Layout table for investigator information
Principal Investigator: Jemima Albayda, MD Johns Hopkins University

Layout table for additonal information
Responsible Party: Johns Hopkins University Identifier: NCT03440034     History of Changes
Other Study ID Numbers: IRB00130996
First Posted: February 20, 2018    Key Record Dates
Last Update Posted: May 29, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Johns Hopkins University:
inclusion body myositis

Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Diseases
Neuromuscular Diseases
Musculoskeletal Diseases
Myositis, Inclusion Body
Muscular Diseases
Hypoglycemic Agents
Physiological Effects of Drugs